Clarifying Timing of Immunotherapy for Advanced Bladder Cancer - Cancer Currents Blog

Having trouble viewing this email? View it as a Web page.

You are subscribed to Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Recent posts are listed below.     Study Clarifies Timing of Immunotherapy for Advanced Bladder Cancer 06/24/2020 Results from a large study show that, for most people with advanced bladder cancer, starting immunotherapy with avelumab (Bavencio) shortly after initial treatment with chemotherapy is better than delaying treatment.

Stay Connected with the National Cancer Institute
Chat with us: LiveHelp       Call us: 1-800-4-CANCER (1-800-422-6237) SUBSCRIBER SERVICES: Manage Subscriptions  |  Help

 

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892